Increase in Leptin and PPAR-γ Gene Expression in Lipedema Adipocytes Differentiated in vitro from Adipose-Derived Stem Cells

Sara Al-Ghadban 1,*, Zaidmara T. Diaz 1, Hallie J. Singer 1, Karya B. Mert 1 and Bruce A. Bunnell 1,2,*

1 Center for Stem Cell Research and Regenerative Medicine, Tulane University, New Orleans, LA 70112, USA; zdiaz@tulane.edu (Z.T.D.); hssinger2@tulane.edu (H.J.S.); kmert@tulane.edu (K.B.M.)
2 Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112, USA
* Correspondence: salghadban@tulane.edu (S.A.-G.); bbunnell@tulane.edu (B.A.B.); Tel.: +1-504-988-7071 (B.A.B.)

Received: 8 January 2020; Accepted: 7 February 2020; Published: 12 February 2020

Abstract: Lipedema is a painful loose connective tissue disorder characterized by a bilaterally symmetrical fat deposition in the lower extremities. The goal of this study was to characterize the adipose-derived stem cells (ASCs) of healthy and lipedema patients by the expression of stemness markers and the adipogenic and osteogenic differentiation potential. Forty patients, 20 healthy and 20 with lipedema, participated in this study. The stromal vascular fraction (SVF) was obtained from subcutaneous thigh (SVF-T) and abdomen (SVF-A) fat and plated for ASCs characterization. The data show a similar expression of mesenchymal markers, a significant increase in colonies \((p < 0.05)\) and no change in the proliferation rate in ASCs isolated from the SVF-T or SVF-A of lipedema patients compared with healthy patients. The leptin gene expression was significantly increased in lipedema adipocytes differentiated from ASCs-T \((p = 0.04)\) and the PPAR-γ expression was significantly increased in lipedema adipocytes differentiated from ASCs-A \((p = 0.03)\) compared to the corresponding cells from healthy patients. No significant changes in the expression of genes associated with inflammation were detected in lipedema ASCs or differentiated adipocytes. These results suggest that lipedema ASCs isolated from SVF-T and SVF-A have a higher adipogenic differentiation potential compared to healthy ASCs.

Keywords: lipedema; adipose-derived stem cells (ASCs); stromal vascular fraction (SVF) adipocyte differentiation; adipogenesis; inflammation

1. Introduction

Lipedema is a painful loose connective tissue disorder that affects approximately 11% of adult women in the United States [1,2]. This disorder is characterized by a symmetrical increase of fat deposition in the legs and the arms, sparing the hands and the feet [3–5]. The symptoms of lipedema are often confused with obesity, lymphedema, chronic venous insufficiency and other fat disorders [6–10]. Lipedema consists of three stages characterized by the texture of skin and tissue formation: Stage 1 has normal smooth skin over pearl-sized nodules in a hypertrophic fat layer; Stage 2 has skin indentations over a hypertrophic fat structure of pearl to-apple-size masses; and Stage 3 has large extrusions of tissue causing skin and fat deformations mainly on the thighs and around the knees. [11–14]. Women with lipedema experience pain, heaviness of the affected limb, psychosocial distress, anxiety, eating disorders and the inability to lose weight as the fat tissue is highly resistant to diet and exercise [2,7,12,15–17]. Symptoms may progress in the advanced stages of lipedema and are associated with increased cardiovascular and renal diseases [1,2].
There is no cure for lipedema. Liposuction is by far the most effective treatment to decrease the fibrotic lipedema fat and thereby maintain mobility, which is essential for the quality of life of women affected by lipedema [18–21]. Complex physical decongestive therapies (CPDT) including manual lymphatic drainage and compression with shock wave therapy (SWT) have been shown to improve the tissue structure and blood circulation [22,23]. A study conducted by Siems et al. showed that treating lipedema patients with CPDT and/or SWT reduced oxidative stress and cellulite, demonstrated by decreased levels of the lipid peroxidation marker (malondialdehyde) and protein carbonyls [24]. Although pain and bruising were still persistent, patients reported the effectiveness of these therapies. Furthermore, clinicians recommend supplements such as bioflavonoids, turmeric and selenium to lipedema patients, as these act as antioxidants which might help in reducing inflammation, improving blood vessels and removing free radicals [2].

While the etiology of lipedema remains unknown, hormones, genetic factors, inflammation, leaky and dilated blood and lymphatic vessels and the thickening of the interstitium are all known to contribute to the pathogenesis [12,25–27]. Our team and others have shown that lipedema adipose tissue is a highly vascularized and fibrotic tissue with an increase in blood vessels, infiltrating macrophages and hypertrophic adipocytes [25,28,29]. Suga et al. showed an increase in the proliferation of adipose-derived stem/progenitor/stromal cells (Ki67+ and CD34+ cells) in the adipose tissue of lipedema patients, indicating an increase in adipogenesis, leading to tissue hypoxia, adipocyte necrosis and macrophage infiltration [28].

Adding to that, Priglinger et al. [29] have characterized adipose-derived stromal/stem cells (ASCs) obtained from lipoaspirates and showed an increase in the number of CD146+ endothelial/pericytic cells in lipedema patients compared to healthy patients, proposing that this increase might be a marker of leaky blood and lymphatic vessels in lipedema adipose tissue. Thus, the expansion of adipose tissue, which is mediated by the increase in adipocyte size (hypertrophy) and/or the proliferation (hyperplasia) and differentiation (adipogenesis) of adipose progenitor cells/pre-adipocytes to mature adipocytes is detected in lipedema adipose tissue. Adipogenesis is a complex cellular differentiation process tightly regulated by key transcription factors such as peroxisome proliferator-activated receptor-γ (PPAR-γ), which in turn controls the expression of several other genes involved in lipogenesis (Lipoprotein lipase, LPL), insulin sensitivity (Glucose transporter type 4, GLUT4) and hormones such as leptin [30–32].

As lipedema primarily manifests in the legs of patients in early stages but extends to other areas in the body as the disease progresses, we characterized ASCs obtained from the subcutaneous adipose tissue of both the thigh (SVF-T) and abdomen (SVF-A) of lipedema patients and healthy controls. A full phenotypic characterization of ASCs as defined by the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT) was performed, as was an evaluation of the gene expression of adipogenic and inflammatory markers in ASCs and differentiated adipocytes. Characterizing ASCs from different fat depots will provide insights into the biology of adipose fat tissue in lipedema patients and will provide a better understanding of their potential application in cellular therapy and regenerative medicine.

2. Materials and Methods

2.1. Participants

A total of forty patients, 20 with lipedema and 20 healthy controls (non-lipedema subjects) participated in this study. Lipoaspirates were harvested from thigh and abdomen obtained from women undergoing elective liposuction. For lipedema patients, both tissues are considered affected as diagnosed by the physicians performing the liposuctions. All subjects provided their informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki and the protocols were approved by the Human Research and Protection Program at the University of Arizona (Institutional Review Board (IRB) protocol number: 1602399502) and Tulane University (IRB protocol number: 9189). Participants were determined to have lipedema...
based on the criteria of Wold et al [4]. All patients’ identifiers were kept confidential and all received samples utilized in this study were de-identified. Table 1 provides the characteristics of the participants. No statistical significance in the age or Body Mass Index (BMI) was observed between the two groups.

| Characteristics | Healthy | Lipedema |
|-----------------|---------|----------|
| Number          | 20      | 20       |
| Sex (M/F)       | Female  | Female   |
| Age (years)     | 46.9 ± 2.2 | 44.1 ± 2.2 |
| BMI (kg/m²)     | 28.5 ± 0.86 | 29.9 ± 0.97 |
| Stage 1         | –       | 15%      |
| Stage 2         | –       | 70%      |
| Stage 2–3       | –       | 5%       |
| Stage 3         | –       | 10%      |

2.2. ASCs Isolation and Cell Culture

ASCs were isolated from lipoaspirates of subcutaneous adipose tissue from the abdomen or thigh. The lipoaspirates were washed with 1X phosphate-buffered saline (PBS) and incubated at 37 °C in a rocking incubator at 100 rpm for 1 h in 0.1% collagenase type 1 (Sigma, St. Louis, MO, USA). The digested tissue was then centrifuged to remove lipids, primary adipocytes and collagenase solution. The SVF pellet containing ASCs was plated in 175 cm² flasks. ASCs were maintained in Dulbecco's modified eagles medium (DMEM)/F12 (Hyclone, Logan, UT, USA) with 10% fetal bovine serum (FBS, Hyclone, Logan, UT, USA) and 1% antibiotic/antimycotic (Thermo Fisher Scientific, Waltham, MA, USA). Media was changed every three days until the cells achieved 80%–90% confluence. ASCs were culture expanded in the same medium and harvested at passage two (p2) with 0.25% trypsin/1 mM EDTA (Thermo Fisher Scientific, Waltham, MA, USA) and used for the experiments. ASCs from lipedema and non-lipedema participants were used at p3, plated at the same cell density and performed for the same duration of time for all the experiments.

The healthy ASCs-T used in this study were a generous gift from Dr. Eleni Priglinger (Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Vienna, Austria).

2.3. Alamar Blue Cell Proliferation Assay

ASCs were seeded at a density of 15.6 × 10³ cells/cm² in a 96-well plate. The cell proliferation was assessed on days 1, 7, 14 and 21 in culture. The cells were incubated with 20 µL of AlamarBlue reagent (Thermo Fisher Scientific, Waltham, MA, USA) for 2 h in an incubator at 37 °C with 5% CO₂. The fluorescence intensity was measured with excitation at 540 nm and emission at 600 nm on a Synergy™ HTX Multi-Mode Microplate Reader (BioTek, Winooski, VT, USA).

2.4. Colony-Forming Unit (CFU) Fibroblast Assay

ASCs were seeded at a density of 0.5 × 10² cells/cm² in a 6-well plate and were cultured for 14 days. The medium was changed on day seven after cell seeding. At day 14, the cells were washed twice with 1X PBS and stained with 1 mL of 3% crystal violet (Sigma, St. Louis, MO, USA) for 30 min at room temperature (RT). The plates were then washed with deionized water and placed on the rocker for 10 min. The number of colonies was manually quantified, with only CFUs greater than 2 mm² in diameter being recorded. Each experiment was performed in triplicate.

2.5. Flow Cytometry

For the phenotypic analysis, the cells were blocked with 1% BSA and 1% CD16/CD32 in 1X PBS and stained with the following antibodies at RT for 15 min: CD3 (Cat #: 562406, BD Biosciences, San Jose,
CA, USA), CD14 (Cat #: IM2640U, Beckman-Coulter, USA), CD31 (Cat #: 563651, BD Biosciences, USA), CD45 (Cat #: A71117, Beckman-Coulter Brea, CA, USA), CD73 (Cat #: 550257, BD Biosciences, USA), CD90 (Cat #: 11-0909-42, Invitrogen, Waltham, MA, USA) and CD105 (Cat #: 17-1057-42, Invitrogen, USA). The cells were then fixed with 1% paraformaldehyde (PFA) and a total of 10,000 events were captured and analyzed with a Gallios Flow Cytometer using Kaluza software (Beckman Coulter, Brea, CA, USA).

2.6. Adipogenic Differentiation and Oil Red O Staining

For the adipogenic differentiation, ASCs were seeded at a density of $2 \times 10^4$ cells/cm$^2$ and grown in DMEM/F12. At confluence, the medium was replaced with adipogenic differentiation-inducing medium (AdipoQual, LaCell, NO, LA, USA) for the differentiation of the cells, or kept in DMEM/F12 medium for control undifferentiated cells. Media was changed every three days until day 21. For staining, the control and differentiated cells were fixed with 4% PFA for 30 min, stained with filtered Oil Red O (Sigma, St. Louis, MO, USA) for 15 min, followed by multiple rinses with 1XPBS. These cells were then visualized using a Nikon Eclipse TE200 with Nikon Digital Camera DXM1200F and Nikon ACT-1 software version 2.7 at 10× and 20× magnification (Nikon, Melville, NY, USA). The absorbance of the Oil Red O eluted by adding 100% isopropanol was measured at 584 nm wavelength by spectrophotometry. The differentiation values are reported as a percent of the undifferentiated, control cells. For the transcriptional analysis, plates were washed twice with 1xPBS and stored at −80 °C for RNA extraction.

2.7. Osteogenic Differentiation and Alizarin Red Staining

For the osteogenic differentiation, the cells were seeded at a density of $2 \times 10^4$ cells/cm$^2$ and grown to confluence in DMEM/F12. Upon reaching confluency, DMEM/F12 media was replaced with osteogenic differentiation medium DMEM/F12 containing 10% FBS, 10 nM dexamethasone (Sigma, St. Louis, MO, USA), 50 µM ascorbic acid-2-phosphate (Sigma, USA) and 20 mM β-glycerophosphate (STEMCELL Technologies, Cambridge, MA, USA). The control cultures were cultured in DMEM/F12 medium. After 28 days, the osteogenic differentiation was analyzed with alizarin red staining, followed by extraction and quantification. For the alizarin red staining of the calcified structures, the cells were fixed in 4% PFA for 30 min at RT and stained with alizarin red solution. For the quantitative analysis of alizarin red staining, the cells were washed with deionized water and incubated with 10% cetylpyridinium chloride (CPC, Sigma, St. Louis, MO, USA) for 1 h. The absorbance was measured at 562 nm wavelength by spectrophotometry.

2.8. RNA Isolation and Quantitative Real-Time PCR (qRT-PCR)

The total RNA from undifferentiated ASCs and from induced-ASCs was extracted using an RNA extraction kit (Qiagen, Germantown, MD, USA) and then digested with DNase I (Qiagen, USA). A total of 1 µg of mRNA was used for the cDNA synthesis Applied Bioscience purification kit (Thermo Fisher Scientific, USA). qRT-PCR was performed using the SYBR Green qPCR SuperMix (Bio-Rad, Hercules, CA, USA), according to the manufacturer’s instructions. Oligonucleotide primers were designed with the vendor’s software (IDT, Coralville, IA, USA). Table 2 lists the primer sequences used for qRT-PCR. The PCR conditions were: 2 min at 95 °C and 40 cycles of 15 s at 95 °C and 30 s at 60 °C. The target and reference genes were amplified in separate wells. All reactions were performed in duplicate. The $2^{-\Delta\Delta Ct}$ method was used to calculate the relative fold change in the gene expression after normalization to GAPDH, which was used as an internal control.
Table 2. List of primers used for real-time quantitative PCR (qRT-PCR).

| Name   | Forward                   | Reverse                   |
|--------|---------------------------|---------------------------|
| IL-6   | 5′-GTAGCCGCCCCACACAGACAGGAC-3′ | 5′-GCCCCACACAGAGGATTC-3′ |
| IL-1β  | 5′-CTCTCTGAGACCCGAGTG-3′ | 5′-TTAGACACCAATGTGCG-3′ |
| TNF-α  | 5′-CCCTCTGAGACCCGAGTG-3′ | 5′-CTCTCTGAGACCCGAGTG-3′ |
| VEGF   | 5′-CCCCTTGTCTTACCTCCAC-3′ | 5′-CACAAGGATGGGCTGAAGA-3′ |
| Glut4  | 5′-AGC AGC TCT CTG GCA TCA AT-3′ | 5′-TCCTGTCCTGTTTAAACCAATTGTT-3′ |
| CD36   | 5′-GAGACCTGTATCCAGAGAAATC-3′ | 5′-CCCTGAGACCCGAGTG-3′ |
| LPL    | 5′-GAGATTTCTCTGTATGGCAG-3′ | 5′-CTGAAAGACATCTTTACT-3′ |
| Leptin | 5′-AGGAGCCGACCCAGACACCAG-3′ | 5′-AGGAGGCTGACCTCACAC-3′ |
| ADIPOQ | 5′-ACATGCCATGGCCTTAC-3′ | 5′-AGGAGGCTGACCTCACAC-3′ |
| GAPDH  | 5′-CGCTGAGATCGTGGGATG-3′ | 5′-AGGAGGCTGACCTCACAC-3′ |

2.9. Statistical Analysis

GraphPad PRISM 8 was used for all statistical analyses. A Mann-Whitney test was used to determine the differences between the two groups of participants. A one-way ANOVA followed by a Tukey’s post hoc test was used to analyze the differences between the four groups. Asterisks (*) indicate statistical significance: * p < 0.05; ** p < 0.01.

3. Results

3.1. Lipedema ASCs Isolated from SVF-T and SVF-A Showed a Significant Increase in CFU with no Change in Stemness Makers or Proliferation Rate Compared to Healthy ASCs

The phenotypic characterization of ASCs was analyzed by flow cytometry for the expression of stemness and surface markers. ASCs isolated from lipedema SVF-T and SVF-A showed a similar expression of mesenchymal stem cell (MSC) markers: CD73, CD90, CD105 to ASCs derived from SVF of healthy patients. CD90 and CD105 were highly expressed in ASC-T and ASC-A (90%–100%) isolated from the two cohort groups; CD73 was expressed in 50% of ASCs-T, but it ranged from 40% (lipedema) to 60% (healthy) in ASCs-A (Figure 1A,D). Other surface markers were expressed at a very low percentage in ASCs-T and ASCs-A of the two groups and they include the T-cell marker (CD3), monocyte/macrophage marker (CD14), endothelial marker (CD31) and the lymphohematopoietic marker (CD45) in ASC-T and ASC-A isolated from both lipedema and healthy patients (Figure 1A,D). Furthermore, the self-renewal potential of ASCs was measured by their ability to form fibroblast-like colonies. The quantitative analysis of the CFU showed a significant increase in the colony-forming potential of ASCs-T (p < 0.01) and ASCs-A (p < 0.05) derived from lipedema patients compared to healthy patients (Figure 1B,E). The cell proliferation was also assessed and the data showed no significant difference in the growth rate between lipedema ASCs-T and ASCs-A as compared to healthy ASCs after 1, 7, 14 and 21 days in culture (Figure 1C,F).
Figure 1. Characterization of (A–C) ASCs-T and (D–F) ASCs-A isolated from SVF-T and SVF-A of healthy and lipedema patients. (A,D) Flow cytometry analysis of the surface marker expression was similar for cultured ASCs between healthy and lipedema patients (n = 10 per group). (B,E) The quantitative analysis of the CFU assay revealed a significant increase in the colony-forming potential of ASCs from lipedema patients compared with healthy patients (ASCs-T: healthy n = 8 and lipedema n = 10; ASCs-A: healthy n = 9 and lipedema n = 8). The results are displayed as scatter plots with bars. The values are the mean ± SEM. * p < 0.05; ** p < 0.01. (C,F) The AlamarBlue assay showed no difference in the proliferation rate of ASCs between healthy and lipedema patients at 1, 7, 14 and 21 days in culture (n = 10 per group).

3.2. Lipedema ASCs Showed Increased Adipogenic but not Osteogenic Differentiation Potential as Compared to Healthy ASCs

ASCs isolated from SVF-T and SVF-A of healthy and lipedema patients were differentiated into adipocytes, as shown by Oil Red O staining (Figure 2A,D) and osteoblasts as determined by alizarin red staining (Figure 2C,F). The quantitative analysis of Oil Red O staining showed a higher adipogenic differentiation potential of lipedema ASCs compared to healthy ASCs (Figure 2B,C), with a significant increase in lipedema ASCs-T (Figure 2B, p < 0.05). No difference was detected in osteogenic differentiation between the two groups, as confirmed by quantitative analysis (Figure S1).
3.3. Significant Increase in Leptin and PPAR-γ Gene Expression in Lipedema Differentiated Adipocytes Compared to Healthy Adipocytes

Adipogenesis of ASCs was further confirmed by qRT-PCR for adipogenic markers: adiponectin, LPL, CD36, Leptin, PPAR-γ and Glut4. Adipocytes differentiated from lipedema ASCs-T and ASCs-A showed an increase in adiponectin, LPL and CD36 gene expression compared to the same cells from healthy ASCs (Figure 3A,B). The increase was statistically insignificant due to the high variability observed in the samples. The leptin and PPAR-γ gene expression showed a significant increase in differentiated adipocytes from lipedema ASCs-T ($p = 0.04$) and ASCs-A ($p = 0.03$), respectively, compared to adipocytes differentiated from Healthy ASCs. The Glut4 gene expression was similar in the differentiated adipocytes of both groups (Figure 3C,D).
Figure 3. The adipogenic differentiation marker genes increased in differentiated adipocytes of lipedema (A,C) ASCs-T and (B,D) ASCs-A as compared to corresponding cells from healthy ASCs. (A,B) The qRT-PCR analysis showed a trend of increase in adiponectin, LPL and CD36 gene expression in differentiated adipocytes of lipedema ASCs-T and ASCs-A as compared to healthy differentiated adipocytes (ASCs-T: \( n = 10 \) per group; ASCs-A: \( n = 8 \) per group). (C,D) The qRT-PCR analysis showed (C) a significant increase in leptin gene expression in differentiated adipocytes of lipedema ASCs-T and (D) a significant increase in PPAR-\( \gamma \) gene expression in differentiated adipocytes of lipedema ASCs-A, with no change in the Glut4 gene expression as compared to healthy differentiated adipocytes (ASCs-T: \( n = 10 \) per group; ASCs-A: \( n = 8 \) per group). The gene expression of differentiated adipocytes are calculated from the percent of undifferentiated, control cells. The results are displayed as scatter plots with bars. The values are the mean ± SEM. * \( p < 0.05 \). Abbreviations: ADIPOQ: adiponectin; LPL: Lipoprotein lipase; PPRA-\( \gamma \): peroxisome proliferator-activated receptor gamma; and CD36: cluster of differentiation 36.

3.4. Inflammatory Genes Expression Was Similar for Lipedema ASCs and Adipocytes Compared to Healthy Cells

As obesity induces adipose tissue remodeling, fibrosis and angiogenesis, these changes alter ASCs’ immune phenotype and function, as demonstrated by the increased expression of pro-inflammatory cytokines, such as interleukin 1 beta (IL-1\( \beta \)), IL-6, tumor necrosis factor-alpha (TNF-\( \alpha \)) and vascular endothelial growth factor (VEGF) [33,34]. Thus, the expression level of these genes was determined in lipedema and healthy ASCs by qRT-PCR. No difference was detected in the gene expression between ASCs-T and ASCs-A isolated from lipedema and healthy patients (Figure 4A,B). However, there was a trend of increase in the gene expression of VEGF, IL-6, IL-1\( \beta \) and TNF\( \alpha \) in adipocytes differentiated from lipedema ASCs-T compared to the same cells differentiated from healthy patients (Figure 4C), but none was detected in adipocytes differentiated from lipedema ASCs-A compared to healthy cells (Figure 4D).
4. Discussion

As lipedema is a chronic, painful fat disorder characterized by a significant expansion of adipose tissue in the lower extremities of the body [5,12], ASCs residing in the adipose niche and stimulated by a plethora of inflammatory and angiogenic factors might contribute to tissue adiposity. ASCs are a heterogeneous population of cells characterized by their ability to adhere to plastic, proliferate in culture, form colonies and differentiate into multiple lineages in vitro and in vivo [35–38].

In this study, ASCs isolated from the SVF-T and SVF-A of 20 lipedema patients and 20 healthy subjects were characterized for their stemness markers, self-renewal ability and differentiation ability to adipocytes and osteoblasts in vitro. The phenotypic characterization of the SVF-T and SVF-A isolated from lipedema patients revealed the differential expression of stemness and surface markers. However, the differences were not statistically significant (Figure S2A). Interestingly, a significant increase in CD31, a vascular endothelial marker, was detected in SVF-T and SVF-A isolated from lipedema patients as compared to SVF-A from healthy patients (Figure S2B). Consistent with this, Priglinger et al. showed a significant increase in the endothelial/pericytic marker CD146 in SVF isolated from the hips and thigh of lipedema patients compared to healthy patients, proposing that this increase might be a marker of repair of leaky blood and lymphatic vessels in lipedema tissues [29].

Priglinger et al. also showed no difference in the MSC markers CD90, CD73 and CD105, as well as in the proliferation rate of ASCs isolated from SVF of lipedema patients compared to healthy
patients [29], which is consistent with our findings on lipedema ASCs isolated from SVF-T but which contradicts the data published by Bauer et al. showing a significant increase in proliferation in lipedema ASCs at day 14 compared to non-lipedema ASCs [39]. Furthermore and in contrast to the data published by Priglinger et al. and Bauer et al., we showed a significant increase in the adipogenic potential of ASCs-T of lipedema patients compared with the same cells from healthy patients. These differences might be due to several factors, including different techniques used to perform the proliferation and differentiation assays, the use of different liposuction techniques, the harvest site and the disease stage of the patients enrolled in the study.

Additionally, we have isolated ASCs from SVF-A obtained from lipedema patients and showed that there is no difference in the expression of MSC markers or the proliferation rate compared with the same cells from healthy patients. Interestingly, lipedema ASCs-A displayed a slower proliferation rate when compared to lipedema ASCs-T, with no difference in their colony forming unit (Figure S3). Nevertheless, there was a significant decrease in the adipogenic and osteogenic differentiation potential of lipedema ASCs-A compared to lipedema ASCs-T (p < 0.05), as shown by the quantitative analysis in Figure S4. There was also a significant decrease in the osteogenic potential in healthy ASCs-A compared to healthy ASCs-T, but no difference was shown in their adipogenic potential (Figure S4A,B). Taken together, these results demonstrate that lipedema and healthy ASCs isolated from two diverse depots of adipose tissue display a distinctive clonogenic and differentiation potential toward adipogenic and osteogenic lineages, confirming the cellular specificity of ASCs, as previously reported several studies [40–42].

Adipogenesis is a complex process of cellular differentiation of ASCs that has been widely used to study metabolic disorders and regenerative medicine [32,43–45]. In vitro, PPAR-γ is a key regulator of adipogenesis and its expression determines the commitment of preadipocytes’ differentiation into mature adipocytes [30,46]. In this study, we showed an increase in the adipogenic differentiation potential of lipedema ASCs isolated from SVF-T and SVF-A, as assessed by the degree of lipid droplet accumulation by Oil Red O stain and the expression of the main adipogenic gene markers: adiponectin, LPL, CD36, Leptin, PPAR-γ and Glut4. The PPAR-γ gene expression showed a significant increase in differentiated adipocytes from lipedema ASCs-A, but not from ASCs-T, compared to adipocytes differentiated from healthy ASCs. Although the PPAR-γ activity has been demonstrated to regulate insulin sensitivity [32,47], no change in the GLUT4 gene expression was detected in adipocytes differentiated from lipedema ASCs as compared to healthy ASCs.

Leptin is known to regulate energy homeostasis by controlling satiety and body weight and has been shown to be highly expressed by adipocytes differentiated from obese ASCs [48–50]. Our data showed a significant increase in differentiated adipocytes from lipedema ASCs-T compared to adipocytes differentiated from healthy ASCs. Comparing the adipogenic gene expression in differentiated adipocytes between the four groups resulted in no statistical difference among the lipedema or healthy groups (data not shown).

Lipedema adipose tissue is highly infiltrated with immune cells instigating an increase in fibrosis and angiogenesis. We and others have shown increased levels of macrophages observed around blood vessels or forming crown-like structures surrounding necrotic adipocytes [25,28,51]. Therefore, we ought to determine the expression levels of inflammatory genes in lipedema ASCs derived from SVF-T and SVF-A. Our results showed no difference in gene expression between ASCs-T and ASCs-A isolated from lipedema and healthy patients. However, there was a trend of increase in the gene expression of VEGF, IL-6, IL-1β and TNFα in adipocytes differentiated from lipedema ASCs-T, which can be correlated with the data we have previously published of a significant increase in macrophages detected by CD68 expression in lipedema adipose thigh fat tissue [25]. Additionally, the increase in VEGF transcription can also be related to previously reported data on elevated levels in the blood of ten women with lipedema compared to controls [24].

Having established the stemness of lipedema ASCs, our next step will be conducting experiments to investigate the usefulness of ASCs in developing a scaffold for tissue engineering and the potential
treatment of the disease. However, one of the main limitations of this study is the scarcity of samples from lipedema patients with stage 1 and stage 3, as well as from lean healthy participants. The ability to conduct studies on lipedema stage 1 patients will provide insights on the early manifestation of the disease and will probably provide clues on how to prevent its progression.

5. Conclusions

In conclusion, we demonstrated that lipedema ASCs isolated from SVF-T show a higher adipogenic differentiation potential compared to lipedema ASCs isolated from SFV-A and healthy ASCs. Although ASCs might induce adipogenesis in lipedema, an in-depth characterization of ASCs will provide a better understating of the pathophysiology of lipedema and probably be a promising tool for lipedema patients.

Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/2/430/s1: Figure S1: Quantitative analysis of alizarin red by spectrophotometry showing no difference in the osteogenic differentiation between healthy and lipedema ASCs-T or healthy and lipedema ASCs-A (n = 4 per group). The results are displayed as scatter plots with bars. The values are the mean ± SEM; Figure S2: Flow cytometry analysis of SVFs. (A) SVFs showed a similar expression of stemness and surface markers between lipedema patients (SVF-A, n = 6; SVF-T, n = 8). (B) CD31 marker expression in SVFs showed a significant increase in lipedema patients compared to healthy patients (SVF-A healthy, n = 8; SVF-T lipedema, n = 6; SVF-A lipedema, n = 9). The results are displayed as scatter plots with bars. The values are the mean ± SEM. *p < 0.05, **p < 0.001; Figure S3: Quantitative analysis of CFU assay revealed a significant increase in the colony-forming potential of lipedema ASCs compared with healthy patients as well as a significant decrease between healthy ASCs-T and lipedema ASCs-A (ASCs-T: healthy n = 8 and lipedema n = 10; ASCs-A: healthy n = 9 and lipedema n = 8). Results are displayed as scatter plots with bars. Values are mean ± SEM. *p < 0.05, **p < 0.01; Figure S4: Quantitative analysis of Oil Red O (A) and Alizarin red (B) by spectrophotometry showing a significant decrease in adipogenic and osteogenic differentiation potential in lipedema ASCs-A compared to lipedema ASCs-T (p < 0.05) and a significant decrease in the osteogenic potential in healthy ASCs-A compared to healthy ASCs-T, but no difference was shown in their adipogenic potential (Adipogenic differentiation ASCs-T: healthy n = 10 and lipedema n = 9, ASCs-A: n = 8 per group, Osteogenic differentiation, n = 4 per group).

Author Contributions: Conceptualization, S.A.-G. and B.A.B.; Data curation, S.A.-G., Z.T.D., H.J.S. and K.B.M.; formal analysis, S.A.-G.; Funding acquisition, B.A.B.; Investigation, S.A.-G.; Methodology, S.A.-G.; Project administration, S.A.-G.; Supervision, B.A.B.; Validation, S.A.-G.; Writing—original draft, S.A.-G.; Writing—review & editing, S.A.-G. and B.A.B. All authors have read and approved the final version of the manuscript.

Funding: This study was supported by the Lipedema foundation. The grant number: 000009.

Acknowledgments: The authors would like to thank Rachel Sabol and Alan Tucker and the Flow Cytometry core for their expertise and Karen Herbst (University of Arizona, AZ), Michael Schwartz (Westlake Village, CA), Marcia Byrd (Roswell, GA), Frank Lau (Louisiana State University, LA) and Eleni Priglinger (Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Austria) for providing the samples used in this study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Buso, G.; Depairon, M.; Tomson, D.; Raffoul, W.; Vettor, R.; Mazzolai, L. Lipedema: A Call to Action! Obesity 2019, 27, 1567–1576. [CrossRef]
2. Herbst, K.L.; Mirkovskaya, L.; Bharagava, A.; Chava, Y.; Te, C.H.T. Lipedema fat and signs and symptoms of illness, increase with advancing stage. Arch. Med. 2015, 7, 1–8. [CrossRef][PubMed]
3. Herbst, K.L. Rare adipose disorders (RADs) masquerading as obesity. Acta Pharmacol. Sin. 2012, 33, 155–172. [CrossRef][PubMed]
4. Wold, L.E.; Hines, E.A.; Allen, E.V. Lipedema of the legs: A syndrome characterized by fat legs and edema. Ann. Intern. Med. 1951, 34, 1243–1250. [CrossRef][PubMed]
5. Al-Ghadban, S.; Herbst, K.L.; Bunnell, B.A. Lipedema: A Painful Adipose Tissue Disorder. In Adipose Tissue—An Update; IntechOpen: London, UK, 2019.
6. Shavit, E.; Wollina, U.; Alavi, A. Lipoedema is not lymphoedema: A review of current literature. Int. Wound J. 2018, 15, 921–928. [CrossRef]
7. Buck, D.W.; Herbst, K.L. Lipedema: A relatively common disease with extremely common misconceptions. Plast. Reconstr. Surg. Glob. Open 2016, 4, e1043. [CrossRef]
8. Fife, E.C.; Maus, A.E.; Carter, J.M. Lipedema: A frequently misdiagnosed and misunderstood fatty deposition syndrome. *Adv. Skin Wound Care* 2010, 23, 81–92. [CrossRef]
9. Beltran, K.; Herbst, K.L. Differentiating lipedema and dercum’s disease. *Int. J. Obes.* 2017, 41, 240–245. [CrossRef]
10. Crescenzi, R.; Donahue, P.M.; Weakley, S.; Garza, M.; Donahue, M.J.; Herbst, K.L. Lipedema and Dercum’s Disease: A New Application of Bioimpedance. *Lymphat. Res. Biol.* 2019, 17, 671–679. [CrossRef]
11. Pascucci, A.; Lynch, P.J. Lipedema with multiple lipomas. *Dermatol. Online J.* 2010, 16, 4. [PubMed]
12. La Torre, Y.S.-D.; Wadeea, R.; Rosas, V.; Herbst, K.L. Lipedema: Friend and foe. *Horm. Mol. Biol. Clin. Investig.* 2018, 33. [CrossRef]
13. Langendoen, S.; Habemma, L.; Nijsten, T.; Neumann, H. Lipoedema: From clinical presentation to therapy. A review of the literature. *Br. J. Dermatol.* 2009, 161, 980–986. [CrossRef]
14. Shin, B.W.; Sim, Y.-J.; Jeong, H.J.; Kim, G.C. Lipedema, a Rare Disease. *Ann. Rehabilitation Med.* 2011, 35, 922–927. [CrossRef]
15. Dudek, J.E.; Białaszek, W.; Ostaszewski, P.; Smidt, T. Depression and appearance-related distress in functioning with lipedema. *Psychol. Heal. Med.* 2018, 23, 846–853. [CrossRef]
16. Szel, E.; Kemény, L.; Groma, G.; Szolnoky, G. Pathophysiological dilemmas of lipedema. *Med. Hypotheses* 2014, 83, 599–606. [CrossRef]
17. Alwardat, N.; Di Renzo, L.; Alwardat, M.; Romano, L.; De Santis, G.L.; Gualtieri, P.; Carrano, E.; Nocerino, P.; De Lorenzo, A. The effect of lipedema on health-related quality of life and psychological status: A narrative review of the literature. *Eat. Weight. Disorder. Stud. Anorexia Bulim. Obes.* 2019, 1–6. [CrossRef]
18. Schmeller, W.; Hueppe, M.; Meier-Vollrath, I. Tumescent liposuction in lipedema yields good long-term results. *Br. J. Derm.* 2012, 166, 161–168. [CrossRef]
19. Didadas, M.; Mallinger, P.J.; Corterier, C.C.; Theodosiadi, S.; Ghods, M. Liposuction in the Treatment of Lipedema: A Longitudinal Study. *Arch. Plast. Surg.* 2017, 44, 324–331. [CrossRef]
20. Baum, S.; Kaak, I.; Kottmann, T.; Podda, M.; Rapprich, S. Treatment of lipedema using liposuction: Results of our own surveys. *Phlebologie* 2015, 44, 121–132. [CrossRef]
21. Peled, A.W.; Kappos, E.A. Lipedema: Diagnostic and management challenges. *Int. J. Women’s Heal.* 2016, 8, 389–395. [CrossRef]
22. Herbst, K.L.; Ussery, C.; Eekema, A. Pilot study: Whole body manual subcutaneous adipose tissue (SAT) therapy improved pain and SAT structure in women with lipedema. *Horm. Mol. Biol. Clin. Investig.* 2017, 33. [CrossRef]
23. Szolnoky, G.; Borsos, B.; Bársnyo, K.; Balogh, M.; Kemény, L. Complete decongestive physiotherapy with and without pneumatic compression for treatment of lipedema: A pilot study. *Lymphology 2008*, 41, 40–41.
24. Siems, W.; Grune, T.; Voss, P.; Brenke, R. Anti-fibro sclerotic effects of shock wave therapy in lipedema and cellulite. *BioFactors* 2005, 24, 275–282. [CrossRef]
25. Al-Ghaddan, S.; Cromer, W.; Allen, M.; Ussery, C.; Badowski, M.; Harris, D.; Herbst, K.L. Dilated Blood and Lymphatic Microvessels, Angiogenesis, Increased Macrophages and Adipocyte Hypertrophy in Lipedema Thigh Skin and Fat Tissue. *J. Obes.* 2019. [CrossRef]
26. Child, A.H.; Gordon, K.D.; Sharpe, P.; Brice, G.; Ostergaard, P.; Jeffery, S.; Mortimer, P.S. Lipedema: An inherited condition. *Am. J. Med Genet. Part A* 2010, 152, 970–976. [CrossRef]
27. Precone, V.; Barati, S.; Paolacci, S.; Salgarello, M.; Visconti, G.; Gentilesciu, S.; Guerri, G.; Gagliardi, L.; Aquilanti, B.; Matera, G.; et al. Genetic syndromes with localized subcutaneous fat tissue accumulation. *Acta Bio-Med. Atenei Parmensis* 2019, 90, 90–92. [CrossRef]
28. Suga, H.; Araki, J.; Aoi, N.; Kato, H.; Higashino, T.; Yoshimura, K. Adipose tissue remodeling in lipedema: Adipocyte death and concurrent regeneration. *J. Cutan. Pathol.* 2009, 36, 1293–1298. [CrossRef]
29. Priglinger, E.; Wurzer, C.; Steffenhagen, C.; Maier, J.; Hofer, V.; Peterbauer, A.; Nuerberger, S.; Redl, H.; Wolbank, S.; Sandhofer, M. The adipose tissue–derived stromal vascular fraction cells from lipedema patients: Are they different? *Cytotherapy 2017*, 19, 849–860. [CrossRef]
30. Chabon, A.L.; Scherer, P.E. Adipogenesis and metabolic health. *Nat. Rev. Mol. Cell Biol.* 2019, 20, 242–258. [CrossRef]
31. Vishvanath, L.; Gupta, R.K. Contribution of adipogenesis to healthy adipose tissue expansion in obesity. *J. Clin. Investig.* 2019, 129, 4022–4031. [CrossRef]
32. White, U.; Ravussin, E. Dynamics of adipose tissue turnover in human metabolic health and disease. *Diabetologia* 2019, 62, 17–23. [CrossRef] [PubMed]
33. Badimon, L.; Cubedo, J. Adipose tissue depots and inflammation: Effects on plasticity and resident mesenchymal stem cell function. *Cardiovasc. Res.* **2017**, *113*, 1064–1073. [CrossRef] [PubMed]

34. Louwen, F.; Ritter, A.; Kreis, N.N.; Yuan, J. Insight into the development of obesity: Functional alterations of adipose-derived mesenchymal stem cells. *Obes. Rev.* **2018**, *19*, 888–904. [CrossRef] [PubMed]

35. Baer, P.C.; Geiger, H. Adipocyte-Derived Mesenchymal Stromal Stem Cells: Tissue Localization, Characterization and Heterogeneity. *Stem Cells Int.* **2012**, *2012*, 1–11. [CrossRef]

36. Bunnell, B.A.; Flaat, M.; Gagliardi, C.; Patel, B.; Ripoll, C. Adipose-derived stem cells: Isolation, expansion and differentiation. *Methods* **2008**, *45*, 115–120. [CrossRef]

37. Guo, J.; Nguyen, A.; Banyard, D.A.; Fadavi, D.; Toranto, J.D.; Wirth, G.A.; Paydar, K.Z.; Evans, G.R.; Widgerow, A.D. Stromal vascular fraction: A regenerative reality? Part 2: Mechanisms of regenerative action. *J. Plast. Reconstr. Aesthetic Surg.* **2016**, *69*, 180–188. [CrossRef]

38. Bourin, P.; Bunnell, B.A.; Casteilla, L.; Dominici, M.; Katz, A.J.; March, K.L.; Redl, H.; Rubin, J.P.; Yoshimura, K.; Gimble, J.M. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: A joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). *Cytotherapy* **2013**, *15*, 641–648. [CrossRef]

39. Bauer, A.-T.; Von Lukowicz, D.; Lossagk, K.; Hopfner, U.; Kirsch, M.; Moog, P.; Bauer, H.; Machens, H.-G.; Schmauss, D. Adipose Stem Cells from Lipedema and Control Adipose Tissue Respond Differently to Adipogenic Stimulation In Vitro. *Plast. Reconstr. Surg.* **2019**, *144*, 623–632. [CrossRef]

40. Patrikoski, M.; Mannerström, B.; Miettinen, S. Perspectives for Clinical Translation of Adipose Stromal/Stem Cells. *Stem Cells Int.* **2019**, *2019*, 1–21. [CrossRef]

41. Cignarelli, A.; Perrini, S.; Ficarella, R.; Pescechera, A.; Nigro, P.; Giorgino, F. Human adipose tissue stem cells: Relevance in the pathophysiology of obesity and metabolic diseases and therapeutic applications. *Expert Rev. Mol. Med.* **2012**, *14*, e19. [CrossRef]

42. Levi, B.; James, A.; Glotzbach, J.P.; Wan, D.C.; Commons, G.; Longaker, M. depot-specific variation in the osteogenic and adipogenic potential of human adipose-derived stromal cells. *Plast. Reconstr. Surg.* **2010**, *126*, 822–834. [CrossRef] [PubMed]

43. Schneider, S.; Unger, M.; Van Griensven, M.; Balmayer, E.R. Adipose-derived mesenchymal stem cells from liposuction and resected fat are feasible sources for regenerative medicine. *Eur. J. Med Res.* **2017**, *22*, 17. [CrossRef] [PubMed]

44. Konno, M.; Hamabe, A.; Hasegawa, S.; Ogawa, H.; Fukusumi, T.; Nishikawa, S.; Ohta, K.; Kano, Y.; Ozaki, M.; Noguchi, Y.; et al. Adipose-derived mesenchymal stem cells and regenerative medicine. *Dev. Growth Differ.* **2013**, *55*, 309–318. [CrossRef] [PubMed]

45. Li, H.; Zimmerlin, L.; Marra, K.G.; Donnenberg, V.S.; Donnenberg, A.D.; Rubin, J.P. Adipogenic potential of adipose stem cell subpopulations. *Plast. Reconstr. Surg.* **2011**, *128*, 663–672. [CrossRef] [PubMed]

46. Rosen, E.D.; Walkey, C.J.; Puigserver, P.; Spiegelman, B.M. Transcriptional regulation of adipogenesis. *Genes Dev.* **2000**, *14*, 1293–1307. [CrossRef] [PubMed]

47. Leonardini, A.; Laviola, L.; Perrini, S.; Natalichio, A.; Giorgino, F. Crosstalk between PPAR γ and insulin signaling and modulation of insulin sensitivity (report). *PPAR Res.* **2009**, *2009*, 1–21. [CrossRef] [PubMed]

48. Stern, J.H.; Rutkowski, J.M.; Scherer, P.E. Adiponectin, Leptin and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. *Cell Metab.* **2016**, *23*, 770–784. [CrossRef]

49. Strong, A.L.; Ohlstein, J.F.; Biagas, B.A.; Rhodes, L.V.; Pei, D.T.; Tucker, H.A.; Llamas, C.; Bowles, A.C.; DuTreil, M.F.; Zhang, S.; et al. Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers. *Breast Cancer Res.* **2015**, *17*, 112. [CrossRef]

50. Scheller, E.L.; Song, J.; Dishowitz, M.I.; Soki, F.N.; Hankenson, K.D.; Krebsbach, PH. Leptin Functions Peripherally to Regulate Differentiation of Mesenchymal Progenitor Cells. *Stem Cells* **2010**, *28*, 1071–1080. [CrossRef]

51. Taylor, N.E.; Foster, W.C.; Wick, M.R.; Patterson, J.W. Tumefactive lipedema with pseudoxanthoma elasticum-like microscopic changes. *J. Cutan. Pathol.* **2004**, *31*, 205–209. [CrossRef]